A 4-miRNA signature act as a novel prognostic biomarker in patients with Sarcoma

BACKGROUND: A sarcoma is a rare form of cancer that can develop throughout the body and has a poor prognosis. Micro RNA may be used as molecular markers in sarcoma patients to predict patient outcomes. METHODS: In this study, miRNA expression data of sarcoma tissues samples were downloaded from The...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xiaotao, Cao, Lumei, Xie, Ningning, Xu, Xiaowei, Liu, Ming, Wang, Kai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797695/
https://www.ncbi.nlm.nih.gov/pubmed/35116884
http://dx.doi.org/10.21037/tcr.2019.07.46
_version_ 1784641613717307392
author Chen, Xiaotao
Cao, Lumei
Xie, Ningning
Xu, Xiaowei
Liu, Ming
Wang, Kai
author_facet Chen, Xiaotao
Cao, Lumei
Xie, Ningning
Xu, Xiaowei
Liu, Ming
Wang, Kai
author_sort Chen, Xiaotao
collection PubMed
description BACKGROUND: A sarcoma is a rare form of cancer that can develop throughout the body and has a poor prognosis. Micro RNA may be used as molecular markers in sarcoma patients to predict patient outcomes. METHODS: In this study, miRNA expression data of sarcoma tissues samples were downloaded from The Cancer Genome Atlas (TCGA) database. The univariable cox regression and log likelihood were performed to screen the miRNAs related with prognosis. The Cox proportional hazard regression model was used to establish a multi-gene prognostic model based on the expression value of the miRNAs. The survival curve was created by the KM method. The interaction network and function annotation of the target genes were analyzed to investigate the mechanism of the key miRNAs. RESULTS: Hsa-miR-190b, hsa-miR-3170, hsa-miR-4762, hsa-miR-18a were identified and used to establish the prediction model. The target genes of the 4 miRNAs were involved in cancer signaling pathways as revealed by KEGG. Cox regression analysis showed that the prognostic model of miRNA was an independent influencing factor in Sarcoma patients (P<0.05). Survival analysis confirmed that the overall survival rate of sarcoma patients with low risk scores was significantly higher than those with high risk scores (P<0.01). CONCLUSIONS: The miRNA prognosis model established in this study can be used to predict the prognosis of Sarcoma patients, and these 4 miRNAs may involve in cancer signaling pathways by regulating these target genes
format Online
Article
Text
id pubmed-8797695
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-87976952022-02-02 A 4-miRNA signature act as a novel prognostic biomarker in patients with Sarcoma Chen, Xiaotao Cao, Lumei Xie, Ningning Xu, Xiaowei Liu, Ming Wang, Kai Transl Cancer Res Original Article BACKGROUND: A sarcoma is a rare form of cancer that can develop throughout the body and has a poor prognosis. Micro RNA may be used as molecular markers in sarcoma patients to predict patient outcomes. METHODS: In this study, miRNA expression data of sarcoma tissues samples were downloaded from The Cancer Genome Atlas (TCGA) database. The univariable cox regression and log likelihood were performed to screen the miRNAs related with prognosis. The Cox proportional hazard regression model was used to establish a multi-gene prognostic model based on the expression value of the miRNAs. The survival curve was created by the KM method. The interaction network and function annotation of the target genes were analyzed to investigate the mechanism of the key miRNAs. RESULTS: Hsa-miR-190b, hsa-miR-3170, hsa-miR-4762, hsa-miR-18a were identified and used to establish the prediction model. The target genes of the 4 miRNAs were involved in cancer signaling pathways as revealed by KEGG. Cox regression analysis showed that the prognostic model of miRNA was an independent influencing factor in Sarcoma patients (P<0.05). Survival analysis confirmed that the overall survival rate of sarcoma patients with low risk scores was significantly higher than those with high risk scores (P<0.01). CONCLUSIONS: The miRNA prognosis model established in this study can be used to predict the prognosis of Sarcoma patients, and these 4 miRNAs may involve in cancer signaling pathways by regulating these target genes AME Publishing Company 2019-08 /pmc/articles/PMC8797695/ /pubmed/35116884 http://dx.doi.org/10.21037/tcr.2019.07.46 Text en 2019 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
spellingShingle Original Article
Chen, Xiaotao
Cao, Lumei
Xie, Ningning
Xu, Xiaowei
Liu, Ming
Wang, Kai
A 4-miRNA signature act as a novel prognostic biomarker in patients with Sarcoma
title A 4-miRNA signature act as a novel prognostic biomarker in patients with Sarcoma
title_full A 4-miRNA signature act as a novel prognostic biomarker in patients with Sarcoma
title_fullStr A 4-miRNA signature act as a novel prognostic biomarker in patients with Sarcoma
title_full_unstemmed A 4-miRNA signature act as a novel prognostic biomarker in patients with Sarcoma
title_short A 4-miRNA signature act as a novel prognostic biomarker in patients with Sarcoma
title_sort 4-mirna signature act as a novel prognostic biomarker in patients with sarcoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797695/
https://www.ncbi.nlm.nih.gov/pubmed/35116884
http://dx.doi.org/10.21037/tcr.2019.07.46
work_keys_str_mv AT chenxiaotao a4mirnasignatureactasanovelprognosticbiomarkerinpatientswithsarcoma
AT caolumei a4mirnasignatureactasanovelprognosticbiomarkerinpatientswithsarcoma
AT xieningning a4mirnasignatureactasanovelprognosticbiomarkerinpatientswithsarcoma
AT xuxiaowei a4mirnasignatureactasanovelprognosticbiomarkerinpatientswithsarcoma
AT liuming a4mirnasignatureactasanovelprognosticbiomarkerinpatientswithsarcoma
AT wangkai a4mirnasignatureactasanovelprognosticbiomarkerinpatientswithsarcoma
AT chenxiaotao 4mirnasignatureactasanovelprognosticbiomarkerinpatientswithsarcoma
AT caolumei 4mirnasignatureactasanovelprognosticbiomarkerinpatientswithsarcoma
AT xieningning 4mirnasignatureactasanovelprognosticbiomarkerinpatientswithsarcoma
AT xuxiaowei 4mirnasignatureactasanovelprognosticbiomarkerinpatientswithsarcoma
AT liuming 4mirnasignatureactasanovelprognosticbiomarkerinpatientswithsarcoma
AT wangkai 4mirnasignatureactasanovelprognosticbiomarkerinpatientswithsarcoma